Bell Bank Has $456,000 Holdings in Danaher Co. (NYSE:DHR)

Bell Bank cut its stake in shares of Danaher Co. (NYSE:DHR) by 56.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,226 shares of the conglomerate’s stock after selling 2,913 shares during the period. Bell Bank’s holdings in Danaher were worth $456,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Norges Bank acquired a new position in Danaher in the fourth quarter valued at about $2,130,740,000. GAMMA Investing LLC grew its stake in Danaher by 24,958.2% in the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate’s stock valued at $383,524,000 after acquiring an additional 1,863,381 shares during the period. Raymond James Financial Inc. acquired a new position in Danaher in the fourth quarter valued at about $391,172,000. Two Sigma Advisers LP grew its stake in Danaher by 4,248.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate’s stock valued at $376,347,000 after acquiring an additional 1,601,800 shares during the period. Finally, Capital World Investors grew its stake in Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate’s stock valued at $1,460,215,000 after acquiring an additional 1,566,658 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Christopher Paul Riley sold 15,805 shares of the company’s stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president now owns 15,179 shares of the company’s stock, valued at approximately $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the company’s stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman now directly owns 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.10% of the company’s stock.

Danaher Price Performance

Shares of NYSE DHR opened at $201.14 on Tuesday. The business’s 50 day moving average price is $193.35 and its two-hundred day moving average price is $210.53. The company has a market cap of $143.95 billion, a PE ratio of 38.09, a price-to-earnings-growth ratio of 2.66 and a beta of 0.77. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a twelve month low of $171.00 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.26. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a return on equity of 10.82% and a net margin of 16.33%. On average, analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.64%. Danaher’s dividend payout ratio (DPR) is presently 24.85%.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of research analyst reports. TD Cowen boosted their target price on Danaher from $240.00 to $248.00 and gave the company a “buy” rating in a research note on Wednesday, April 23rd. UBS Group cut their price target on Danaher from $275.00 to $240.00 and set a “buy” rating on the stock in a report on Wednesday, April 23rd. Wells Fargo & Company cut their price target on Danaher from $240.00 to $210.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 23rd. HSBC cut their price target on Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Finally, Jefferies Financial Group cut their price target on Danaher from $260.00 to $230.00 and set a “buy” rating on the stock in a report on Tuesday, April 22nd. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $248.17.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.